UNSPSC 51182000: Androgens and androgen inhibitors

This classification denotes compounds that interact with, amplify, or inhibit androgen receptors in target tissues to bring about the effects similar to those of testosterone. depending on the target tissues, androgenic effects can be on sex differentiation, male reproductive organs, spermatogenesis, secondary male sex characteristics, libido, development of muscle mass, strength, and power.

UNSPSC 51182000 Androgens and androgen inhibitors, a Class code, encompasses pharmaceutical products that state and local governments procure through cooperative purchasing agreements and direct supply contracts with manufacturers and wholesalers. In practice, the code captures a narrow slice of a much broader procurement activity: state and local agencies solicit generic multi-source pharmaceuticals and over-the-counter products through cooperative vehicles that bundle multiple therapeutic classes, including androgens and androgen inhibitors, under unified pricing and supply-chain frameworks. The issuing bodies are primarily state purchasing offices and multistate cooperative alliances administering on behalf of participating state agencies, local government facilities, and in some cases subordinate state health systems. Recent activity shows state purchasing offices using cooperative purchasing mechanisms to aggregate demand across multiple jurisdictions and facility types, negotiating directly with manufacturers for National Drug Code-specific products and enforcing compliance with cGMP, the Drug Supply Chain Security Act, and FDA requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving state and local government facilities across Minnesota, Oregon, and other participating jurisdictions. The procurement emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with EDI and administrative data formats, and vendor relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with awarded contracts effective July 1, 2026. Vendors must maintain comprehensive insurance, supply products with at least one-year expiration dates and six-month shelf life, and accept performance penalties ranging from $200 to $1,500 per violation for late reporting or onboarding failures. The contract term spans two years for new vendors with optional extensions at MMCAP's discretion, while incumbent amendments align with existing expiration dates through June 30, 2028.